Exscientia’s Post

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic

This week in the antibody paper journal club blog we are highlighting the following (links in the comment below): 1. Fast and accurate modeling and design of antibody-antigen complex using tFold, where authors update on tfold-AB including modeling of the complex with the antigen, with applications to virtual screening. Authors: Fandi Wu, Yu Zhao, Jiaxiang Wu et al. #bindingPrediction #structurePrediction #docking 2. Digger: directed annotation of immunoglobulin and T cell receptor V, D, and J gene sequences and assemblies. Novel tool to automatically annotate immunoglobulin (and t-cell) genes from assemblies. Authors: William D Lees, Swati Saha, Gur Yaari, Corey T Watson #annotation #numbering 3. AntiFold: Improved antibody structure design using inverse folding, where authors inverse folding method specific to antibodies. Authors: Magnus Høie, Alissa Hummer, Tobias Olsen, Morten Nielsen, Charlotte Deane #generativeMethods #proteinDesign 4. In vitro validated antibody design against multiple therapeutic antigens using generative inverse folding, where authors use inverse folding method for redesign of binding antibodies from crystal structures, experimentally validated. Authors: Amir Shanehsazzadeh, Julian Alverio, George Kasun, et al. #proteinDesign #generativeMethods Key points and links to these publications and more can be found on the NaturalAntibody Resources blog: https://lnkd.in/d4zsgR6v

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. #MicroRNA #miRNA #RNAsynthesis #syntheticbiology #Biotech

CSCCG, AMI BioScience, offers "Outsourcing facilities for mRna Expression studies using qPCR Techniques" Established Laboratory Facility: Molecular Biology facilities, Cell culture facilities, FACS facilities and Genomics Data analysis platform https://lnkd.in/gXV3mQw https://lnkd.in/fP9wZrH https://lnkd.in/ghrefqPZ #amibioscience, #Biotechnology,#molecularbiology, #gene, #genecloning, #rtpcr, #qpcr, #geneexpression, #mrna, #moleculabiologylab, #westernblot, #rnabloting, #snpanalysis, #multiplexpcr, #sangersequencing, #westernblotting, #mrnacloning, #mirnaexperssion #training, #Cancer, #Project, #flowcytometry, #flowcytometryanalysis, #cellcyclearrest, #drug, #drugdeveloment, #cancerdrug, #cancerresearch, #cancercellline, #stemcell, #stemcellresearch, #flowcytometrytest, #apoptosis, #researchproject, #biotechlab, #biotechnologylab, #cellculturefacility, #cellculturelab, #cancercellculture, #cancerproject, #geneexpression, #cancerlab, #pharmaceuticalproject, #medicalresearch, .#cancercells, #Cellculture, #molecularbiology ,

Our very own Principal Scientist, Daniel Miller is the featured expert in EditCo Bio’s upcoming webinar: AI-driven identification and validation of novel synthetic lethal gene pairs.  The webinar will discuss how Evariste leverages AI to accelerate drug discovery, utilizing EditCo's CRISPR Express Cell Pools and Arctoris' Ulysses® to drive rapid target validation. Topics covered include: 🔬 Synthetic lethality (SL) as a promising, untapped oncology strategy, with currently limited actionable targets. 🔍 How Evariste uses Frobenius Target to identify novel SL gene pairs and validates them using high-throughput CRISPR editing and robotic cell biology assays. 💡 Case study on a novel SL pair involving the oncology target FAK, showcasing the platform’s ability to identify a pipeline of clinically actionable targets. Danny will be joined by industry leaders Travis Hardcastle from EditCo and Kinga Bercsenyi from Arctoris. Their expertise, combined with Danny's insights, will make this a must-attend webinar! 🗓️ Date: 18th July, 12:00 EST 📝 Register now: https://lnkd.in/ePREsEJX #Evariste #EditCo #Arctoris #AIDrugDiscovery #SyntheticLethality #TechBio #CRISPR

We presented a poster at #BioITExpo last week on the single-cell RNA sequencing (#scRNA-seq) analysis we performed in collaboration with Marengo Therapeutics. The publication, published in Science Advances, details the analysis on tumor-infiltrating leukocytes (#TILs) in response to mSTAR1302 treatment in vivo. Our BioIT poster detailed our #scRNAseq computational workflow, which involved quality control, count normalization, selection of highly variable genes, dimensionality reduction, cell clustering, and subsequent annotation. Click here to view the poster and see how we dissected transcriptional profiles of complex biological systems at a single cell level: https://lnkd.in/e6qVryxf

🤗 Find us at Booth 517, Festival of Biologics 2024 in San Diego from April 15-17. Don't miss Xiaoyuan Ran's talk on "Transforming Tumor Research: Engineering MHCs as Versatile Reagents" today at 3pm. 📊 Poster Presentations: Explore our innovative research through five engaging posters: #77: Transforming Tumor Research: Engineering MHCs as Versatile Reagents #78: GPCR VLPs & Nanodiscs for Drug Discovery #79: Tailored AAV Solutions: ELISA Kits and Customized Variant Kit Development #80: Enhancing Cell Therapy with GMP-Grade Cas9 Nuclease Exhibiting Superior Quality and Batch Consistency in Gene Editing #81: The Second-Generation High-Fidelity Cytosine Base Editor AccuBaseTM Can Proficiently Modify Multiple Genes Within A Human Primary T cell While Minimizing Off-target Effects #KACTUS #festivalofbiologicsUSA #Biotech #Innovation #DrugDiscovery #antibodytherapeutics #antibodydiscovery

 ✨ The B6-HATXN3 mouse model is a significant advancement in SCA3 research, offering crucial insights into the genetic mutations causing spinocerebellar ataxia type 3. ✅ This model closely mirrors SCA3's pathology, aiding in preclinical studies, biomarker identification, and therapy evaluation. ✅ The TurboKnockout technology enhances its versatility for genetic diversity representation in patients, supporting drug screening and pharmacological studies. Cyagen's introduction of the B6-HATXN3 model highlights their commitment to medical research progress in SCA3 treatment. Learn more about this mouse model here: https://lnkd.in/d9iRFQmr #mousemodels #preclinicalresearch #research #science #biotech #biotechnology #genetherapy

“When we first started working together, nobody was interested in RNA. We couldn't get funding. We couldn't get papers published. But we saw the potential and we saw enormous potential, and as we were doing our work, the data kept supporting an enormous potential.” And thank goodness they did! This week’s #SciencEE features Drew Weissman, MD, PhD, 2023 The Nobel Prize in Medicine! Famously known for his groundbreaking, nobel-prize winning work in #mRNA science, Dr. Weissman joined our recent scientific symposium to discuss the potential of lipid nanoparticles to deliver gene editing therapies to treat #cysticfibrosis. Thank you to our 2024 #CFAwarenessMonth Tier 2 sponsors — Boehringer Ingelheim, Viatris, 4D Molecular Therapeutics, ReCode Therapeutics, Baxter International Inc. and Enterprise Therapeutics — for supporting our #SciencEE series! #CrossOutCF #CFAwarenessMonth #CFAwareness #CysticFibrosis Penn Medicine, University of Pennsylvania Health System